Overview

[14C] Study to Investigate the Mass Balance and Biotransformation of WPV01 in Healthy Adult Chinese Male Participants

Status:
COMPLETED
Trial end date:
2023-08-06
Target enrollment:
Participant gender:
Summary
This is a single-center, non-randomized, open-label, single-dose, Phase I clinical study to evaluate the mass balance and biotransformation, safety and tolerability of WPV01 in healthy adult chinese male participants following a single oral administration of \[14C\] WPV01.
Phase:
PHASE1
Details
Lead Sponsor:
Westlake Pharmaceuticals (Hangzhou) Co., Ltd.